GlassScriptPhysician profile
Giancarlo Moscol
NPI 1508094392
$68,767.25
in general payments reported to CMS, 2019-2025
30 companies · $20K in 2025
The $20K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,266 · 2020: $8,759 · 2021: $6,730 · 2022: $6,819 · 2023: $12K · 2024: $8,735 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Travel and Lodging: $5,288 · Food and Beverage: $5,241 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Long Term Medical Supply Or Device Loan: $1,265 · Honoraria: $200 · Education: $37.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,162.33 |
| Travel and Lodging | $5,287.72 |
| Food and Beverage | $5,240.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Long Term Medical Supply Or Device Loan | $1,264.84 |
| Honoraria | $200.00 |
| Education | $37.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,257.68 | 2019-2025 | Imfinzi, Enhertu, Truqap |
| Novartis Pharmaceuticals Corporation | $17,080.61 | 2019-2025 | Kisqali |
| Incyte Corporation | $5,100.08 | 2020-2022 | |
| Athenex Pharmaceutical Division, LLC | $4,025.00 | 2020 | |
| Gilead Sciences, INC. | $3,916.79 | 2022-2025 | Trodelvy |
| Avyxa Pharma, LLC | $3,852.92 | 2025 | |
| Pfizer INC. | $2,425.00 | 2021-2023 | |
| Genentech USA, INC. | $2,171.17 | 2019-2021 | |
| Tersera Therapeutics LLC | $1,420.00 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $933.33 | 2025 | |
| Beigene USA, INC. | $727.62 | 2023-2024 | Brukinsa |
| Halozyme INC | $610.00 | 2024 | |
| Cepheid | $610.00 | 2020 | |
| Astellas Pharma US INC | $500.00 | 2021 | |
| Lilly USA, LLC | $482.76 | 2022-2023 | Verzenio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $439.00 | 2023 | |
| Cardinal Health 110 LLC | $400.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Daiichi Sankyo INC. | $313.23 | 2023-2025 | Enhertu |
| Puma Biotechnology, INC. | $186.55 | 2024-2025 | |
| Gen-Probe, INC. | $149.66 | 2023 | Btx |
| Karyopharm Therapeutics INC. | $126.36 | 2021 | |
| Rigel Pharmaceuticals, INC. | $124.40 | 2019 | |
| Stemline Therapeutics INC. | $121.85 | 2023 | Orserdu |
| Genzyme Corporation | $115.00 | 2019 | |
| Clovis Oncology, INC. | $112.63 | 2019 | |
| Servier Pharmaceuticals LLC | $96.26 | 2022 | |
| Napo Pharmaceuticals INC | $79.00 | 2022 | |
| Glaxosmithkline, LLC. | $24.21 | 2020 | |
| Amgen INC. | $16.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giancarlo Moscol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.